Alzheimer's disease (AD) is a chronic neurodegenerative disorder, which is characterized by the accumulation of amyloid plaques and neurofibrillary tangles in specific regions of the brain, accompanied by impairment of the neurons, and progressive deterioration of cognition and memory of affected individuals. Although the cause and progression of AD are still not well understood, the amyloid hypothesis is dominant and widely accepted. According to this hypothesis, an increased deposition of amyloid-β peptide (Aβ) in the brain is the main cause of the AD's onset and progression. There is increasing body of evidence that blood-brain barrier (BBB) dysfunction plays an important role in the development of AD, and may even precede neuron degeneration in AD brain. In the early stage of AD, microvasculature deficiencies, inflammatory reactions, surrounding the cerebral vasculature and endothelial dysfunctions are commonly observed. Continuous neurovascular degeneration and accumulation of Aβ on blood vessels resulting in cerebral amyloid angiopathy is associated with further progression of the disease and cognitive decline. However, little is known about molecular mechanisms that underlie Aβ induced damage of neurovascular cells. In this regards, this review is aimed to address how Aβ impacts the cerebral endothelium. Understanding the cellular pathways triggered by Aβ leading to alterations in cerebral endothelial cells structure and functions would provide insights into the mechanism of BBB dysfunction and inflammatory processes in Alzheimer's, and may offer new approaches for prevention and treatment strategies for AD.
Introduction
Alzheimer's disease is a chronic neurodegenerative disorder, which affects approximately 10% of the population at age 65 and 40% of people over the age 80. AD is characterized by the accumulation of amyloid plaques and neurofibrillary tangles accompanied by impairment of the neurons in specific regions of the brain. In particular, large neurons in the neurocortex, the entorhinal area, hippocampus, amygdale, nucleus basalis, anterior thalamus, and several brain stem monoaminergic nuclei are affected. In damaged regions, the neurons exhibit multiple abnormalities of cell structure and function, reduction in the level of synaptic proteins, and, finally, they die. 1 The neuronal loss in AD brains is accompanied by progressive deterioration of cognition and memory of affected individuals.
The rest of the disease process, including formation of neurofibrillary tangles containing tau protein, is proposed to result from an imbalance between Aβ production and Aβ clearance. Aβ is derived from amyloidogenic cleavage of membrane bound amyloid precursor protein (APP) by -and -secretase.
3
Amyloidogenic processing of the APP leads to the production of Aβ peptides of different length, of which the Aβ 1-40 is the major species and the Aβ 1-42 is the most fibrillogenic and predominant component in AD plaques. 4 There is major evidence which supports Amyloid Cascade Hypothesis. The first comes from the link between AD and Down's Syndrome. The APP gene is localized on chromosome 21, and people with Down Syndrome (trisomy 21) who, thus, have an extra gene copy almost invariably develop AD-like neuropathology by the age of 40. Secondly, inherited mutations in the APP and presenilin genes (presenilin constitutes the catalytic site of the γ-secretase) cause early and aggressive forms of AD. And thirdly, transgenic mice with mutant form of human APP develop amyloid fibrillar plaques and Alzhemer's like brain pathology. 2 Recent reports have suggested that the soluble oligomeric form of the peptide is the most toxic and responsible for the disruption of synaptic plasticity, neuronal death and decline of cognitive function. 5, 6 Although precise mechanism of Aβ oligomers neurotoxic effects remains unclear, in-vivo and in-vitro studies have demonstrated that Aβ oligomers: a) induce apoptosis; b) initiate oxidative stress and free-radical degeneration in neuronal cells; c) disrupt calcium homeostasis and long-term potentiation; d) cause neurodegeneration by forming large, voltage independent, and nonselective ion channels. 7, 8 However, for the most cases of late-onset sporadic non-inherited AD (~95%), the reasons of increased Aβ accumulation in brains remain unknown. In this regard, current theories imply that AD is mainly caused by vascular risk factors, and that vascular derived pathology is responsible for initiation and/or progression of AD.
9-11
Recent studies provided significant data supporting the notion that the pathophysiology of blood brain barrier (BBB) and imbalanced interaction between cerebral endothelial cells (CECs), glial cells and neurons may trigger the progressive destruction of cortical neurons in AD.
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Blood-Brain Barrier Disorder in AD
The homeostasis of the Central Nervous System (CNS) is maintained by the BBB, which separates the brain from the circulating bloodstream. The BBB is formed by a complex cellular system consisting of CECs, astrocytes, pericytes, perivascular macrophages, and a basement membrane (Fig 1. ). CECs layer is a major component of the BBB which is comprised of high-density cells connected by tight junctions. CECs have a little number of endothelial pores, rich in mitochondria, and have a very low content of the pinocytic vesicles. The biomechanical properties of the CECs are critical to the regulation of many cellular functions, such as adhesion, signaling and morphology, and play a vital role for the maintenance of the BBB permeability, and brain parenchyma homeostasis. Astrocytes, the most frequent cells of the brain, also play an important role in maintaining BBB function. Their end feet tightly connected to the CECs influencing cerebrovascular tone and the barrier properties of endothelium. 20 In vitro, amyloid beta peptide has been shown to induce significant dysfunctions in the CECs. Specifically, Aβ suppressed CECs proliferation and migration, affected tube formation in the human brain endothelial cells (HBEC), induced endothelial autophagy through the dissociation of ERK and AKT signaling and intracellular regulation of class 3 phosphatidylinositol 3-kinase.
35,36
Physiological concentrations of soluble Aβ (10 -9 -10 -6 M) induced dose-dependent reduction of NO production, decreased sensitivity of neurovasculature to an endothelium dependent vasodilator acetylcholine, increased cellular calcium level, initiated albumin transfer across EC monolayer and impaired EC glucose uptake.
24,37-39
Higher concentrations of Aβ have been demonstrated to induce mitochondria dysfunction, nuclear chromatin condensation, DNA fragmentation, and significant cerebral endothelial cell death.
37,38,40
Continuous neurovascular degeneration and accumulation of Aβ on blood vessels resulting in cerebral amyloid angiopathy is associated with further progression of the disease and cognitive decline 14,15,17,41,42
Oxidative Stress, Inflammation, and Downstream Cell Signaling Pathways in AD
There is increasing evidence that oxidative stress is a main mechanism leading to cerebrovascular dysfunction in AD. Several studies of transgenic mice over expressing APP have demonstrated oxidative damage of CECs, up regulation of superoxide dismutase (SOD) around brain micro vessels, and significant impairment of the cerebrovascular functions. [43] [44] [45] At the same time, endothelial dysfunctions were not observed in mice over expressing both APP and SOD-1 or in a case when SOD was directly applied to the cerebral cortex of the APP mice. 44 In vitro, treatment of CECs with Aβ increased free radical production and this effect was attenuated by free radical scavengers.
43,46
The oxidative stress initiates a cascade of redox reactions which trigger apoptosis. Several studies have indicated that Aβ -induced CECs death had an apoptotic nature and was a result of the mitochondria dysfunction, activation of a caspase upstream, and proapoptotic proteins release 38, 40, 47, 48 Aβ induced oxidative stress also triggers downstream kinase cascades leading to neurovascular inflammation.
49,50
Study of the microvessels isolated from the AD patients brains have revealed significantly higher levels of interleukin-1β (IL-1β), IL-6, tumor necrosis factor α (TNF-α), microvessel-associated monocyte chemoattractant protein (MCP-1) and IL-1βs. 49 In-vitro, the exposure of Recent studies have indicated that the receptor for advanced glycation endproducts (RAGE) is a binding site for Aβ. [57] [58] [59] [60] [61] [62] RAGE is a multiligand cell surface receptor which is normally expressed in brain endothelium and, at low levels, in microglia and neurons.
15, 60, 61 However, in AD brains RAGE expression is increased by several-fold in cerebral endothelial cells, astrocytes, microglia, and neurons. 60, 61 ROS have been reported to be generated by NADPH oxidase through the RAGE in endothelial cells. 62, 63 Inhibition studies have indicated that anti-RAGE IgG significantly suppressed oxidative stress and inflammation induced by Aβ in vascular cells and neurons. 57 RAGE binding to Aβ has been also demonstrated to regulate Aβ transport across BBB, upregulate pro-inflammatory cytokines and adhesion molecules in CECs, and contribute to the transport of Aβ from the cell surface into the intracellular space in cortical neurons 61, 64, 65 Aβ-induced cytotoxic effects are also associated with the activation of MAPK/ERK1/2 cascade and that activated ERKs (extracellular-signalregulated kinases) is the central target of RAGE. 62, [66] [67] [68] [69] [70] [71] [72] The ERKs are widely expressed protein kinases, part of a signal transduction system, through which extracellular stimuli are transduced. Activation of the ERKs occurs in response to growth factor stimulation, cytokines, virus infection, transforming agents, carcinogens, and after the activation of high-affinity IgG receptors. 71 ERKs have been implicated in diverse cellular responses such as mitogenesis, differentiation, inflammation and cytotoxicity, and the overproduction of this enzyme is involved in many neurodegenerative diseases, including AD. 67, 73, 74 Thus, NADPH oxidase, ERKs and RAGE have been suggested to be important therapeutic targets in AD.
Permeability of Cerebral Endothelium in AD
In the AD, an increased deposition of Aβ in the cerebral vasculature has been found to correlate with accumulation of monocytes in the vessel walls and of activated microglia cells in the adjacent parenchyma. [75] [76] [77] Since peripheral monocytes can migrate across the BBB and differentiate into microglia, 78 which, in turn, drives the disease development towards exacerbation of the oxidative and inflammatory conditions characteristic of the AD brain, several research groups have attempted to demonstrate the direct effect of Aβ on endothelial functions leading to enhanced transmigration of monocytes.
In-vitro studies have shown that soluble Aβ interactions with RAGE and platelet-endothelial cell adhesion molecule-1 (PECAM-1) at the apical surface and basolateral sides of monolayer of brain endothelial cells increased transendothelial migration of monocytic cells. [79] [80] [81] Based on the observation that the permeability of the monolayer toward dextran and inulin in the presence or absence of Aβ 42 remained unaltered, 79 it has been concluded that enhanced transmigration of monocytes induced by Aβ is not only due to nonspecific disruption of the barrier properties of the endothelial layer, but also is a consequence of Aβ induced expression of the chemokines and adhesion molecules. Since primary capture of the monocytes to endothelium and rolling are mediated by tethering on selectins and selectin ligands, [82] [83] [84] the expression of adhesion molecules, mechanical properties of the membranes (fluidity, elasticity) and membrane-cytoskeleton interactions are critical for transmigration. force microscopy and quantitative immunofluorescence microscopy studies have demonstrated that Aβ oligomers induced P-selectin expression, increased cell stiffness, decreased the apparent rupture force of selectin-ligand bonding due to dissociation of adhesion between the cytoskeleton and the bilayer membrane, and, thus, increased probability of adhesion. 91 The presence of the tight junctions of high electrical resistance and close cell-cell contact are important biomechanical factors maintaining brain homeostasis and BBB impermeability. Tight junction is a complex of transmembrane proteins (occluding, claudins, junctional molecule-1) and submembrane molecules connected to actin network. In fact, the structure and functions of the tight junctions are strongly affected in the cerebrovascular cells of AD patients. 92 In an animal model of AD, a cholesterolenriched diet down-regulated the expression of the occluding and ZO-1, which was strongly correlated with the elevated level of the BBB leakage. 93 In vitro, treatment of primary rat CECs with Aβ 1-42 for 3 days altered expression of occluding and claudin-1, caused relocation of plasma membrane subunits of claudin-5 and ZO-2 to the cytoplasm. At the same time, the cytoplasmic ZO-1 and ZO-2 where evenly distributed along the plasma membrane at the points of the cell-cell contacts. 94 Apolipoprotein E4 (apoE4), a major risk factor for AD, has been shown to be involved in tight junction alteration as well. 95 It has been shown that mice deficient in apoE have expressed BBB leakage. In vitro study has demonstrated that the barrier functions of tight junctions was impaired when the CECs were reconstituted with primary astrocytes from apoE4-knock-in mice. In particular, the phosphorylation of occludin and the activation of protein kinase C (PKC)η in CECs were attenuated.
These findings suggest that the effects of Aβ on actin and tight junction protein complexes, as well as vascular risk factors cause the alteration of endothelial layer integrity and contribute to the enhanced transmigration of monocytes across the BBB. Thus, studying the Aβ-mediated alterations in endothelial adhesion and BBB permeability would provide insights into the mechanism of BBB dysfunction and may provide information for developing new targeted drug delivery vehicles 96 for the AD brain.
Conclusion
Chronic neurovascular dysfunctions and degeneration of endothelium are observed in the all stages of AD. Numerous in vivo and in vitro studies have demonstrated that vascular deposition of amyloid beta peptide induces oxidative stress in cerebral vasculature, triggers inflammatory processes and apoptosis, promotes expression of adhesion molecules, affects tight junctions, changes mechanical properties of the CECs membranes, and enhances transmigration of immune cells across BBB. Continuous degeneration of CECs impairs BBB permeability and leads to leakage of blood cells, plasma components and neurotoxic substances into the brain parenchyma. Breakdown of blood brain barrier functions drives the disease development towards exacerbation of the oxidative and inflammatory conditions characteristic of the AD brain and contributes to further progression of the disease. Understanding the precise molecular mechanisms underlying A-mediated oxidative stress in CECs, the effects of Aβ 42 on the BBB adhesion and permeability should prove to provide new insights into the development of preventive and treatment strategies for AD. 
